User profiles for Freja Kirsebom
 | Freja KirsebomUK Health Security Agency, previously Imperial College London Verified email at ukhsa.gov.uk Cited by 4455 |
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Background COVID-19 vaccines have been used for 9 months in the UK. Real world data
have demonstrated the vaccines to be highly effective against COVID-19, severe disease and …
have demonstrated the vaccines to be highly effective against COVID-19, severe disease and …
Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
Neutrophils do not impact viral load or the peak of disease severity during RSV infection
F Kirsebom, C Michalaki, M Agueda-Oyarzabal… - Scientific Reports, 2020 - nature.com
Lung and airway neutrophils are a hallmark of severe disease in infants with respiratory
syncytial virus (RSV)-induced lower respiratory tract infections. Despite their abundance in the …
syncytial virus (RSV)-induced lower respiratory tract infections. Despite their abundance in the …
Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA. 4-5) bivalent vaccines against hospitalisation …
Background In England, the Joint Committee for Vaccination and Immunisation recommended
a spring 2023 booster programme for all adults aged 75 years and older and the …
a spring 2023 booster programme for all adults aged 75 years and older and the …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …
England starting on 14 September 2021. We used a test-negative case–control design to …
COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England
The omicron (B. 1.1. 529) variant, first detected in the UK on Nov 27, 2021, rapidly became
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in sequenced …
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in sequenced …
Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …
in highly vaccinated populations has raised concerns about the effectiveness of current …
Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
The Omicron variant has been associated with reduced vaccine effectiveness (VE) against
mild disease with rapid waning. Meanwhile Omicron has also been associated with milder …
mild disease with rapid waning. Meanwhile Omicron has also been associated with milder …
Protection against symptomatic infection with delta (B. 1.617. 2) and omicron (B. 1.1. 529) BA. 1 and BA. 2 SARS-CoV-2 variants after previous infection and …
AA Powell, F Kirsebom, J Stowe… - The Lancet Infectious …, 2023 - thelancet.com
Background Little is known about protection against SARS-CoV-2 infection following previous
infection with specific individual SARS-CoV-2 variants, COVID-19 vaccination, and a …
infection with specific individual SARS-CoV-2 variants, COVID-19 vaccination, and a …
